Press Releases

Press Releases

Enrollment continues in the pivotal DUPLEX and PROTECT studies of sparsentan DUPLEX Study of sparsentan in FSGS enrolled first 190 patients required for interim proteinuria analysis Net product sales increased to $47.8 million SAN DIEGO , May 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc.
May 11, 2020
SAN DIEGO , April 27, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2020 financial results on Monday, May 11, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
Apr 27, 2020
Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board SAN DIEGO , April 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Suzanne L. Bruhn , Ph.D. to the Company’s Board of Directors, effective immediately. Dr.
Apr 09, 2020
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its fourth quarter and full year
Feb 24, 2020
SAN DIEGO , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in February and March: 9th Annual SVB Leerink Global Healthcare Conference Date: Wednesday, February 26, 2020 Time: 9:30
Feb 19, 2020
SAN DIEGO , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
Feb 10, 2020
SAN DIEGO , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2019 to be approximately $47 million .
Jan 13, 2020